scholarly journals Vitamin B12 Blood Level is Correlated with Drug-Induced Extrapyramidal Symptoms in Schizophrenic Patients

2019 ◽  
Vol 70 (2) ◽  
pp. 630-632
Author(s):  
Emilia Burada ◽  
Ileana Marinescu ◽  
Otilia Constantina Rogoveanu ◽  
Amelia-Mihaela Dobrescu ◽  
Cito Taisescu ◽  
...  
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Blood Level ◽  
Serum Levels ◽  
Extrapyramidal Symptoms ◽  
Blood Levels ◽  
Antipsychotic Treatment ◽  
Drug Induced ◽  
Schizophrenic Patients

The extrapyramidal symptoms (EPS) are commonly associated with antipsychotic treatment of schizophrenic patients. Accumulated evidence has shown that pathways of homocysteine and folate metabolism are linked to neurodegeneration and schizophrenia. The purpose of our study was to evaluate the homocysteine, vitamin B12 and folate serum levels in relation to drug-induced EPS in schizophrenic patients. The blood levels of homocysteine, vitamin B12 and folic acid were measured by chemiluminescent and electrochemoluminescence immunoassay methods in 34 patients diagnosed with schizophrenia (19 patients with severe EPS and 15 controls without EPS), recruited from Clinical Hospital of Neuropsychiatry Craiova, Romania. A significant association has been observed between EPS and vitamin B12 levels, the patients with severe EPS showed a reduced vitamin B12 levels (p=0.02). No correlation was observed between severe EPS and homocysteine or folate levels (p=0.2, respectively p=0.37). Our study suggests that deficiency of vitamin B12 blood levels is correlated with severe EPS in schizophrenic patients. Further studies included more patients and functional experiments are required to clarify the role of these biomarkers in relation with antipsychotic-induced EPS in schizophrenia.

Serum levels of folic acid, vitamin B12, and iron in anemia of pregnancy

1966 ◽  
Vol 96 (3) ◽  
pp. 310-315 ◽  
Author(s):  
Fred Benjamin ◽  
Frank A. Bassen ◽  
Leo M. Meyer
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Serum Levels

scholarly journals FOLIC ACID, VITAMIN B12, AND DNA METHYLATION: AN UPDATE.

2018 ◽  
Vol 11 (1) ◽  
pp. 17 ◽  
Author(s):  
Bhongir Aparna Varma ◽  
Srilatha Bashetti ◽  
Rajagopalan Vijayaraghavan ◽  
Kumar Sai Sailesh
Keyword(s):  
Dna Methylation ◽  
Folic Acid ◽  
Vitamin B12 ◽  
The Body ◽  
Aberrant Methylation ◽  
Restricted Diet ◽  
Current Review ◽  
Folate And Vitamin B12 ◽  
Methylation Patterns

 Epigenetics is one of the exciting and fastest expanding fields of biology; this is above genetics. Methylation is the process involved in the transfer of methyl group to amino acids, proteins, enzymes and DNA of all the cells, and tissues of the body. During cell-division low folate availability may result in decreased production of thymidine wherein uracil may be substituted in the place of thymidine in the DNA sequence. It was reported that folate and Vitamin B12 restricted diet resulted in aberrant methylation patterns. The current review was undertaken to explore the role of folic acid and Vitamin B12 in DNA methylation.

scholarly journals Serum levels of homocystiene, vitamin B12 and folic acid in Indian patients with psoriasis: results of a pilot study

2016 ◽  
Vol 7 (3) ◽  
pp. 276-279 ◽  
Author(s):  
Gaytri Khatri ◽  
Vikram K Mahajan ◽  
Karaninder S Mehta ◽  
Krishan K Sharma ◽  
Satya Bhushan ◽  
...  
Keyword(s):  
Folic Acid ◽  
Pilot Study ◽  
Vitamin B12 ◽  
Serum Levels ◽  
Indian Patients

scholarly journals Folic Acid and Vitamin B12 Administration in CKD, Why Not?

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 383 ◽  
Author(s):  
Irene Capelli ◽  
Giuseppe Cianciolo ◽  
Lorenzo Gasperoni ◽  
Fulvia Zappulo ◽  
Francesco Tondolo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Folic Acid ◽  
Cardiovascular Risk ◽  
Vitamin B12 ◽  
Therapeutic Target ◽  
Direct Action ◽  
Blood Levels ◽  
Traditional Risk Factors ◽  
Stage Renal Disease ◽  
End Stage

Patients affected by chronic kidney disease (CKD) or end-stage renal disease (ESRD) experience a huge cardiovascular risk and cardiovascular events represent the leading causes of death. Since traditional risk factors cannot fully explain such increased cardiovascular risk, interest in non-traditional risk factors, such as hyperhomocysteinemia and folic acid and vitamin B12 metabolism impairment, is growing. Although elevated homocysteine blood levels are often seen in patients with CKD and ESRD, whether hyperhomocysteinemia represents a reliable cardiovascular and mortality risk marker or a therapeutic target in this population is still unclear. In addition, folic acid and vitamin B12 could not only be mere cofactors in the homocysteine metabolism; they may have a direct action in determining tissue damage and cardiovascular risk. The purpose of this review was to highlight homocysteine, folic acid and vitamin B12 metabolism impairment in CKD and ESRD and to summarize available evidences on hyperhomocysteinemia, folic acid and vitamin B12 as cardiovascular risk markers, therapeutic target and risk factors for CKD progression.

Normal serum levels of vitamin B12 and folic acid in children with phenylketonuria

1995 ◽  
Vol 154 (10) ◽  
pp. 866-866 ◽  
Author(s):  
Pietro Strisciuglio ◽  
Daniela Concolino ◽  
Maria Teresa Moricca ◽  
Loris Rivalta ◽  
Giuseppe Parlato
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Serum Levels ◽  
Normal Serum

scholarly journals Hydroxocobalamin. I. Blood Levels and Urinary Excretion of Vitamin B12 in Man After a Single Parenteral Dose of Aqueous Hydroxocobalamin, Aqueous Cyanocobalamin and Cyanocobalamin Zinc-Tannate Complex

Blood ◽  
1961 ◽  
Vol 18 (5) ◽  
pp. 511-521 ◽  
Author(s):  
GEORGE B. JERZY GLASS ◽  
HELEN R. SKEGGS ◽  
DUK HO LEE ◽  
E. LINN JONES ◽  
WILLIAM W. HARDY
Keyword(s):  
Urinary Excretion ◽  
Vitamin B12 ◽  
Blood Level ◽  
Intramuscular Injection ◽  
Serum Vitamin ◽  
Blood Levels ◽  
Parenteral Dose ◽  
Single Intramuscular Injection

Abstract A single intramuscular injection of 500 or 1000 µg. of hydroxocobalamin to 17 individuals resulted in a 1.8- to 4.1-times higher mean serum vitamin B12 blood level, respectively, 5 hours after injection; a 4.6- and 12.8-times higher level 24 hours after injection; a 2.4- and 5.2-times higher level 72 hours after injection, and a 1.6- and 2.4-times higher level by the 2nd through the 4th week after injection than identical doses of cyanocobalamin administered to 19 individuals. The vitamin B12 blood levels following i.m. administration of 500 or 1000 µg. of hydroxocobalamin were significantly higher during the first 24 and 48 hours, respectively, than they were after a cyanocobalamin zinc-tannate complex given to 17 individuals at identical doses. After a single i.m. injection of 500 or 1000 µg. of hydroxocobalamin, an average of only 16 per cent and 27 per cent, respectively, of the vitamin B12 was lost in the 72-hour urines, as compared to 60 per cent and 69 per cent, respectively, after identical doses of cyanocobalamin. These differences, again, were highly significant statistically. The results of these studies give evidence of a slower rate of urinary excretion of hydroxocobalamin as compared to that of cyanocobalamin, and of its ability to build up consistently higher and more prolonged vitamin B12 levels in the blood.

Sign in / Sign up

Export Citation Format

Share Document